Table 2.
Summary of duration of gastrointestinal TEAEs that resolved in patients in EVOLVE-MS-1
| TEAEs occurring in at least 2% of patients | Overall population, N = 696 | ||
|---|---|---|---|
| All events, n (%) | Events that resolveda, n (%) |
Duration in days, median (10th–90th percentile) | |
| Gastrointestinal TEAEs, all events | 215 (30.9) | 191 (88.8) | 7.5 (1–87) |
| Diarrhea | 75 (10.8) | 68 (90.7) | 5.0 (1–63) |
| Nausea | 47 (6.8) | 43 (91.5) | 4.0 (1–86) |
| Upper abdominal pain | 31 (4.5) | 24 (77.4) | 5.0 (1–94) |
| Vomiting | 25 (3.6) | 24 (96.0) | 1.0 (1–14) |
| Constipation | 24 (3.4) | 14 (58.3) | 16.0 (3–120) |
| Abdominal pain | 17 (2.4) | 14 (82.4) | 8.0 (1–52) |
| Flatulence | 15 (2.2) | 9 (60.0) | 19.0 (1–120) |
| Gastroesophageal reflux disease | 14 (2.0) | 7 (50.0) | 86.0 (1–167) |
Data cutoff date March 30, 2018
TEAE treatment-emergent adverse event
aOf events with complete start and end dates